Ganesh Benzoplast Limited (GBL) is pleased to announce the signing of definitive agreements with Cisternina Logistics Private Limited (CLPL), a bulk liquid and gas storage and logistics platform to be majority owned by funds managed and advised by KKR, a leading global investment firm. Pursuant to this transaction, GBL will sell and transfer its liquid storage tank business at terminals located at the Jawaharlal Nehru Port (JNP), Goa Port and Cochin Port on a slump sale basis, as well as its shareholding in ILSL Rail Logistics Private Limited, which will operate the Rail Logistics Business situated in Daund. The aggregate consideration for the transaction is INR 1,154 crore, subject to the terms as detailed in the definitive agreements.

Strategic Business Sale

The completion of the transaction remains subject to necessary regulatory and shareholders’ approvals and is expected to occur in tranches over the next 18-24 months. GBL will consider enhancement of shareholder value by corporate actions viz. buyback as per the regulatory provisions. Further, GBL shall utilize the proceeds from the sale to grow and expand its capacity for manufacturing of chemicals, food preservatives and lube oil additives, chemical trading, and to execute higher value projects in the EPC business.

Future Growth Plans

In addition to the above, CLPL has entered into definitive documents to engage GBL for EPC relating to the expansion, construction and building of pipelines and tanks at the JNP facility. The EPC related services are expected to generate additional revenue of approx. INR 280 crore (excluding taxes) to GBL over the next 18-24 months.

Speaking on the transaction, Mr. Rishi Pilani, chairman and managing director of GBL, said, “GBL has built a strong liquid storage and logistics business over several decades, and we believe Cisternina and KKR are well positioned to support its next phase of growth. The management is focused on growing and expanding the chemical business by adding new product lines and increasing the scale of the EPC business. We would like to thank our shareholders for their continued support in helping us build the business to this scale.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Ganesh Benzoplast Limited

Ganesh Benzoplast Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Ganesh gains 33.7% over three months and trades near its 52-week highs. The PEG of 1.35 sits close to fair value. The stock is neither a clear buy nor obviously expensive. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 93% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 33.7% in three months on -0.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Ganesh Benzoplast Limited.

Valiant Organics Limited (VALIANTORG) is set to hold its Annual General Meeting (AGM) for FY 2025–26 on September 2026. This meeting will provide shareholders with a comprehensive overview of the company’s financial performance and strategic initiatives for the past fiscal year. Valiant Organics Limited, one of the largest chlorophenol derivatives manufacturers globally, has a diversified product range and a robust business model that spans multiple industries including pharmaceuticals, dyes, pigments, and agrochemicals.

Company Overview

Incorporated in 1984, Valiant Organics Limited is headquartered in Mumbai, India. The company specializes in manufacturing and marketing specialty chemicals, with key chemistries including chlorination, hydrogenation, ammonolysis, acetylation, sulphonation, and methoxylation. With a total production capacity of 80,000 TPA and over 900 employees, the company operates six manufacturing units across five locations, including five zero liquid discharge plants.

Financial Highlights

The company’s consolidated financial performance has shown steady growth. For FY 2025–26, the operational revenue stood at INR 912 Cr, with an EBITDA margin of 14.58%. The EBITDA for the year was INR 133 Cr, and the PAT margin was 8.60%. The company’s net debt to equity ratio improved, reflecting a strengthened balance sheet. The return on capital employed (ROCE) and return on equity (ROE) also indicate robust financial health.

As a result of the AGM, shareholders will gain insights into Valiant Organics Limited’s strategic direction, including future growth plans and operational efficiencies. The meeting will also highlight the company’s diversified client base and its strategic location advantages, which contribute to its competitive edge in the market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Valiant Organics Limited

Valiant Organics Limited belongs to the Basic Materials › Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Valiant gains 45.1% over three months and trades near its 52-week highs. Thin margins at 7.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -11.1% CAGR. That signals structural headwinds, not a short-term blip. Buyers show up with 1.6x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 45.1% in three months. Yet revenue grows at only -11.1% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Valiant Organics Limited.

Anupam Rasayan India Limited (BSE: 543275, NSE: ANURAS), one of India’s leading custom synthesis and specialty chemical companies, has concluded the acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share, marking its third strategic inorganic transaction and expanding its presence into finished dosage formulations.

Strategic Milestone

The acquisition, undertaken through Mates Visa Consultancy, a wholly owned subsidiary of Anupam Rasayan, follows the definitive agreement signed on May 23, 2026, and the subsequent completion of the mandatory open offer process. With the acquisition now finalized, Bliss GVS Pharma becomes an integral part of Anupam Rasayan’s expanding portfolio of businesses across specialty chemicals and pharmaceuticals.

Financial and Operational Synergy

The transaction has been funded through a combination of a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec. The financing structure enables Anupam Rasayan to fund the acquisition while preserving balance-sheet capacity for future growth and expansion.

Future Growth Prospects

On the acquisition, Mr. Anand Desai, Managing Director of Anupam Rasayan India Ltd., said, “We are pleased to announce the successful completion of the acquisition of Bliss GVS Pharma. This transaction marks an important milestone in our long-term strategy to build a diversified, integrated and innovation-led global pharmaceutical platform. The acquisition strengthens our presence in finished pharmaceutical formulations and complements Anupam Rasayan’s expertise in key starting materials, intermediates and specialty chemicals.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anupam Rasayan India Limited

Anupam Rasayan India Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Anupam moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 6.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. Sellers drive 1.8x the volume of buyers. Furthermore, they controlled 17 of recent sessions versus 13 for buyers — a clear distribution signal. Revenue grows at 14.1% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 6.1% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Anupam Rasayan India Limited.